Katherine W. Roche, Ph.D.

Senior Investigator

Receptor Biology Section

NINDS

View Site

Building 35, Room 2C-903
35 Convent Drive
Bethesda, MD 20892-3704

301-496-3800

rochek@mail.nih.gov

Research Topics

Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system, and in addition to its central role in fast excitatory signaling it is also involved in synaptogenesis, synaptic plasticity, and the pathogenesis of certain neurologic diseases. Although glutamate acts as a neurotransmitter in all pathways of the central nervous system, the response to glutamate is not uniform at all glutamatergic synapses and varies with the type of glutamate receptor expressed on the postsynaptic membrane. In this context, we are interested in studying synapse-specific expression of postsynaptic NMDA and metabotropic glutamate receptors. My laboratory characterizes the molecular mechanisms underlying neurotransmitter receptor transport and localization at the synapse using several research strategies which include (1) defining sorting motifs present in neurotransmitter receptor cytosolic domains, (2) isolating neurotransmitter receptor-associated proteins, and (3) determining the role of protein-protein interactions in trafficking and specific synapse localization. Using these cell biological approaches, we hope to elucidate the mechanisms of neurotransmitter receptor trafficking in neurons and the role of accessory proteins at central synapses.

Biography

Dr. Roche received her B.S. from Duke University. In 1995 she received her Ph.D. from Johns Hopkins University, where she worked with Richard Huganir studying the regulation of glutamate receptors. She then did a postdoctoral fellowship with Robert Wenthold in the NIDCD, where she investigated the cell biology of glutamate receptor transport and localization. Dr. Roche joined NINDS as an Investigator in 2001. The main focus of her laboratory is the study of neurotransmitter receptor expression and targeting to the synapse.

Selected Publications

  1. Mota Vieira M, Nguyen TA, Wu K, Badger JD 2nd, Collins BM, Anggono V, Lu W, Roche KW. An Epilepsy-Associated GRIN2A Rare Variant Disrupts CaMKIIα Phosphorylation of GluN2A and NMDA Receptor Trafficking. Cell Rep. 2020;32(9):108104.
  2. Nguyen TA, Wu K, Pandey S, Lehr AW, Li Y, Bemben MA, Badger JD 2nd, Lauzon JL, Wang T, Zaghloul KA, Thurm A, Jain M, Lu W, Roche KW. A Cluster of Autism-Associated Variants on X-Linked NLGN4X Functionally Resemble NLGN4Y. Neuron. 2020;106(5):759-768.e7.
  3. Paskus JD, Tian C, Fingleton E, Shen C, Chen X, Li Y, Myers SA, Badger JD 2nd, Bemben MA, Herring BE, Roche KW. Synaptic Kalirin-7 and Trio Interactomes Reveal a GEF Protein-Dependent Neuroligin-1 Mechanism of Action. Cell Rep. 2019;29(10):2944-2952.e5.
  4. Jeong J, Han W, Hong E, Pandey S, Li Y, Lu W, Roche KW. Regulation of NLGN3 and the Synaptic Rho-GEF Signaling Pathway by CDK5. J Neurosci. 2023;43(44):7264-7275.
  5. Vieira MM, Peng S, Won S, Hong E, Inati SK, Thurm A, Thiam AH, Kim S, Myers SJ, Badger JD 2nd, Traynelis SF, Lu W, Roche KW. A Frameshift Variant of GluN2A Identified in an Epilepsy Patient Results in NMDA Receptor Mistargeting. J Neurosci. 2024;44(4).

Related Scientific Focus Areas

This page was last updated on Tuesday, September 3, 2024